Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Drive Competitive Performance

Metrics are central to efforts to rein in clinical trials that are either poorly initiated or have incurred unforeseen events, which place the original timelines and/or budgets at risk of overages. They also drive competitive performance among those organizations performing trials.

Business Intelligence (BI) has become an increasingly popular topic in clinical trials as clinical project managers are expected to make smarter decisions on intelligence derived from clinical trial data and sponsors/CROs are looking for ways to incorporate BI into the eClinical systems they are using to empower oversight - turning raw trail data into actionable information.

Having technology which can automate or assist in the timely monitoring of trials is a huge improvement over the current 'status quo' of manual methods such as spreadsheets, which are cumbersome and erroneous, not to mention only provide a dated snap-shot of trial performance. But how do metrics drive performance competitiveness?

In this webinar we will explore:

  • Business Intelligence: The need to make smarter decisions on intelligences derived from clinical trial data
  • Industry trends on data mining and analytics
  • The need for industry benchmarking across trials & its inherent challenges
  • Moving beyond benchmarking to gamification, efficient resource allocation, and predicative analytics or forecasting

This webinar is applicable to:

  • Sponsor and CRO roles responsible for site selection and activation
  • Sponsor and CRO roles responsible for collecting and evaluating trial metrics

Presenters:

Barry Milton
Barry is a clinical trial and operations management expert. His experiences as an Oncology nurse, clinical trial coordinator and his senior management roles at Novartis, Roche, Merck, and AstraZeneca provides him with a well-rounded set of skills and experiences in the clinical trial space.
BARRY MILTON
Head of Business Operations
Novartis
Jeff Kasher is a known pharmaceutical development change expert with 28 years of experience at Eli Lilly. He is passionate for improving outcomes, bringing patients and research sites into the development process, and dramatically decreasing time to market. His expertise includes novel product development from bench through market launch, research and clinical trial leadership, innovation center start up as well as new industry paradigm creation.

Jeff is President of Patients Can't Wait, Chairman of Advisory Board for DrugDev as well as member of Advisory Board of TrialReach, Cytolon, and goBalto. He sits on the DPharm steering committee and faculty, and is a member of Linking Leaders. In 2013 CenterWatch Jeff was named one of the "20 Innovators Changing the Face of the Clinical Trials Industry." He received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral Fellowship in Physiology at Yale University School of Medicine.
JEFF KASHER
President
Patients Can't Wait
Jeff Kasker
Rob Wynden
Rob has been a computer scientist and programmer for over 30 years in the scientific programming, e-commerce, biotech, and health care industries. He implemented study startup and CTMS functionality at 9 bay area biotech companies, and invented a method that allows medical and biotech organizations to use cloud-based analytics to monitor patient data. He holds a BS in Computer Engineering from Sacramento State University and a PhD in Biological and Biomedical Clinical Informatics from UCSF.
ROB WYNDEN
VP Technology & Engineering
goBalto

Need more information?

Contact us with your questions or to schedule a demo.